Camurus announces NDA resubmission of weekly and monthly buprenorphine depots to FDA
Lund, Sweden — 28 May 2018 — Camurus AB (Nasdaq STO, CAMX) announced today that its US partner Braeburn has resubmitted the New Drug Application (NDA) for CAM2038 weekly and monthly buprenorphine depot injections to the US Food and Drug Administration (FDA) in response to a Complete Response Letter (CRL) received in January 2018. CAM2038 is being developed for the treatment of adults with moderate to severe opioid use disorder, representing a huge global healthcare problem and a public health crisis in the US. We are very pleased that the NDA filing for our weekly and monthly